Singapore, Dec. 5 -- Opioid misuse, addiction, and overdoses have caused significant social and economic burdens leading to the opioid crisis. LT1001 (brand name Naldebain(R)) is a prodrug of nalbuphine, an abuse-free analgesic that has been marketed worldwide for decades. Naldebain(R) is developed by Taiwan based biotech company Lumosa Therapeutics as the world's first extended-release analgesic injection for the relief of moderate/severe post-operative pain for 7 days without the side effects associated with opioids. Naldebain(R) was approved by the Taiwan Food and Drug Administration (TFDA) in March 2017.

A considerable amount of clinical data and use experience have accumulated since product launch. With confirmed safety and efficacy...